We performed immunohistochemical analyses on tumor tissues from four treated groups to assess whether YAP inhibitor combined with trastuzumab therapy, which acts through the AKT/mTOR and ERK/mTOR pathways can be replicated in vivo. Here, AKT1 is linked to neoplasm.